ClinicalTrials.gov
public full text
Public Domain
Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the basis of modern immunosuppression. Tacrolimus is superior to CsA in terms of acute rejection and graft function. However, Tacrolimus increases 2 times the risk of NODAT as compared to CsA.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce#1214770
- Comparison of the Two Immunosuppressive Regimens Based on Tacrolimus and Cyclosporine Following Kidney Transplantation#1211007
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients#881054
- Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens#883137
- Immune System in Diabetic Kidney Disease#429714
Record · ID 1195528
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive